Cargando…
A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645992/ http://dx.doi.org/10.1186/2051-1426-3-S2-P167 |
| _version_ | 1782400908264472576 |
|---|---|
| author | Katz, Matthew Todd, Bauer W Varadhachary, Gauri Acquavella, Nicolas Petroni, Gina Bullock, Timothy Slingluff, Craig L Rahma, Osama |
| author_facet | Katz, Matthew Todd, Bauer W Varadhachary, Gauri Acquavella, Nicolas Petroni, Gina Bullock, Timothy Slingluff, Craig L Rahma, Osama |
| author_sort | Katz, Matthew |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4645992 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46459922015-11-20 A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer Katz, Matthew Todd, Bauer W Varadhachary, Gauri Acquavella, Nicolas Petroni, Gina Bullock, Timothy Slingluff, Craig L Rahma, Osama J Immunother Cancer Poster Presentation BioMed Central 2015-11-04 /pmc/articles/PMC4645992/ http://dx.doi.org/10.1186/2051-1426-3-S2-P167 Text en Copyright © 2015 Katz et al. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Katz, Matthew Todd, Bauer W Varadhachary, Gauri Acquavella, Nicolas Petroni, Gina Bullock, Timothy Slingluff, Craig L Rahma, Osama A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer |
| title | A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer |
| title_full | A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer |
| title_fullStr | A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer |
| title_full_unstemmed | A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer |
| title_short | A randomized multicenter Phase Ib/II study to assess the immunological effect of chemoradiation therapy (CRT) in combination with pembrolizumab compared to CRT alone in resectable or borderline resectable pancreatic cancer |
| title_sort | randomized multicenter phase ib/ii study to assess the immunological effect of chemoradiation therapy (crt) in combination with pembrolizumab compared to crt alone in resectable or borderline resectable pancreatic cancer |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645992/ http://dx.doi.org/10.1186/2051-1426-3-S2-P167 |
| work_keys_str_mv | AT katzmatthew arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT toddbauerw arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT varadhacharygauri arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT acquavellanicolas arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT petronigina arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT bullocktimothy arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT slingluffcraigl arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT rahmaosama arandomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT katzmatthew randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT toddbauerw randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT varadhacharygauri randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT acquavellanicolas randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT petronigina randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT bullocktimothy randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT slingluffcraigl randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer AT rahmaosama randomizedmulticenterphaseibiistudytoassesstheimmunologicaleffectofchemoradiationtherapycrtincombinationwithpembrolizumabcomparedtocrtaloneinresectableorborderlineresectablepancreaticcancer |